BioSpace News Archive

Statera Biopharma (Nasdaq: STAB), announced today the enrollment and randomization of the first patient, with several more in screening for an initial study to evaluate STAT-205 as a potential treatment to mitigate SARS-CoV-2 progression, the virus that causes COVID-19.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the company has initiated a global Phase 2 study to evaluate the safety and efficacy of lumasiran, an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in patients with recurrent kidney stone disease and elevated urinary oxalate levels.

Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the first quarter of fiscal year 2022, the period ended November 30, 2021, after the close of the financial markets on Thursday, January 6, 2022.